Psychedelic drugs, once pushed to the margins of medicine, are rapidly moving into the mainstream, and ibogaine is now at the center of that shift. Renewed attention from the Trump administration has sparked widespread debate, with experts, policymakers, and patients closely watching what could be a turning point in mental health treatment.
In a surprising move, President Donald Trump recently signed an executive order aimed at accelerating research and access to psychedelic therapies. The initiative includes funding to help states explore how these substances could treat conditions like depression, PTSD, and addiction - issues at the heart of the ongoing mental health crisis.
Among the many psychedelics under discussion, ibogaine stands out as the only drug specifically named in the order. This has fuelled curiosity about its potential and raised questions about whether it could soon gain regulatory approval.
Ibogaine is a naturally occurring psychoactive compound derived from the root of the African plant Tabernanthe iboga. Traditionally used in spiritual rituals in Central Africa, it has gained attention in modern medicine for its potential to treat opioid addiction, depression, and trauma-related disorders.
Unlike conventional medications, ibogaine appears to act on multiple brain systems at once. Researchers believe it may “reset” neural pathways linked to addiction and mental health conditions, offering relief where traditional treatments have failed.
Also read:Kerala Issues Alert on Amoebic Meningoencephalitis: Health Minister Warns Public Over Water Safety Risks
The US Food and Drug Administration (FDA) is now under pressure to evaluate ibogaine more quickly. According to officials, the drug could be placed on an accelerated review pathway, with decisions potentially made in months rather than years.
Ibogaine has also received investigational clearance, allowing it to be studied in human clinical trials across the United States. This marks a major milestone, as it opens the door for domestic research that was previously limited due to strict regulations.
Ibogaine is extracted from the iboga plant in Central Africa (Pic: AP/CNN)
Despite growing interest, ibogaine remains classified as a Schedule I substance by the Drug Enforcement Administration, meaning it is considered to have high abuse potential and no accepted medical use. However, if approved by the FDA, it could be administered in controlled clinical settings under strict supervision.
Source: India Latest News, Breaking News Today, Top News Headlines | Times Now
